Baranowski Lyn 4

What Happened Lyn Baranowski, CEO of Avalyn Pharma (AVLN), was granted a derivative award covering 501,033 shares on 2026-04-29. The reported acquisition price is $0.00, indicating an equity award/option rather than an open-market purchase. No cash was reported as exchanged in this transaction.

Key Details

• Transaction date: 2026-04-29; Form 4 filed 2026-05-01 (timely filing).
• Transaction code: A (grant/award); 501,033 underlying shares; price reported $0.00 (derivative).
• Vesting (per footnote): 25% of the shares underlying this option vest and become exercisable on September 12, 2025; the remaining 75% vests in 36 equal monthly installments thereafter, subject to continued service.
• Shares owned following the transaction: not specified in the provided filing details.
• No 10b5-1 plan, tax-withholding sale, or late-filing flag reported in the provided data.

Context This was a grant of an equity award/option, meaning Baranowski received the right to acquire shares in the future as they vest — it is not an immediate open-market purchase or sale. Such awards are common for executives as compensation tied to continued service and performance; they do not by themselves indicate immediate buying or selling intent. Retail investors should note the vesting schedule to see when shares could become exercisable or sellable.